RT-PCR for Inv (16) Quantitative Test

No, fasting is not necessary for this test.

The test requires a sample of your blood or bone marrow.

Your healthcare provider may suggest this test if you exhibit symptoms indicative of AML, or if you have been previously diagnosed with AML and the efficacy of your treatment needs to be evaluated.

This test detects and quantifies the Inv (16) fusion gene in your blood or bone marrow sample. The presence and quantity of this gene can indicate the severity of AML-M4Eo and the effectiveness of the treatment.

The frequency of this test depends on your healthcare provider's advice, which will be based on your diagnosis, treatment plan, and how well you respond to the treatment.

Normally, the Inv (16) fusion gene is not present in the body. However, in individuals diagnosed with AML-M4Eo, the aim of the treatment is to minimize the levels of this fusion gene.

No special precautions are needed before this test. However, it's important to inform your healthcare provider about any medications you're taking as they could potentially interfere with the test results.

Certain medications and the presence of other genetic abnormalities may affect the results of this test.

An oncologist or a hematologist would be the appropriate specialists to consult in the case of abnormal test results.

The primary condition associated with the presence and an elevated level of the Inv (16) fusion gene is AML-M4Eo. The levels of this fusion gene can decrease with effective treatment.

For this test, a healthcare professional will draw a blood sample from a vein in your arm or collect a bone marrow sample through a procedure known as bone marrow aspiration or biopsy.

The test carries minimal risk. You may experience slight pain and bruising at the site of the blood draw or bone marrow aspiration. In very rare cases, there could be a risk of infection.

The presence of the Inv (16) fusion gene strongly indicates AML-M4Eo. However, your healthcare provider will typically use this test in conjunction with other diagnostic tests and clinical findings to confirm a diagnosis.

Yes, the results of this test can be used as a prognostic factor. Lower levels of the Inv (16) fusion genepost-treatment often indicate a better prognosis. Regular monitoring of this gene's levels can help your healthcare provider adjust your treatment plan as necessary.

The RT-PCR for Inv (16) Quantitative Test plays a critical role in the diagnosis and management of AML- M4Eo. While the test provides valuable information, it's essential to remember that open communication with your healthcare provider is crucial to understanding your overall health and treatment plan.